Reata Pharmaceuticals, Inc. (RETA)
Price:
172.36 USD
( + 0.04 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Genmab A/S
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
NEWS
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-04-18 12:15:00NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-04-16 12:15:00NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-04-11 12:15:00NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-04-09 12:15:00NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-04-04 12:30:00NEW YORK, NY / ACCESSWIRE / April 4, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-04-02 12:30:00NEW YORK, NY / ACCESSWIRE / April 2, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-28 12:15:00NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-26 12:30:00NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-21 12:30:00NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-19 12:15:00NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-14 12:15:00NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-12 12:30:00NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-07 12:20:00NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-05 12:30:00NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-02-29 12:20:00NEW YORK, NY / ACCESSWIRE / February 29, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock
prnewswire.com
2024-01-08 08:00:00SHERMAN, Texas, Jan. 8, 2024 /PRNewswire/ -- TO: All persons and entities who, during the period between November 14, 2016 through December 8, 2021 inclusive, purchased or otherwise acquired the common stock of Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) (the "Settlement Class"), including all persons or entities who purchased or otherwise acquired Reata common stock pursuant and/or traceable to Reata's 2019 Offering and/or 2020 Offering (the "Offerings Subclass"). PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
No data to display
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-04-18 12:15:00NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-04-16 12:15:00NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-04-11 12:15:00NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-04-09 12:15:00NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-04-04 12:30:00NEW YORK, NY / ACCESSWIRE / April 4, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-04-02 12:30:00NEW YORK, NY / ACCESSWIRE / April 2, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-28 12:15:00NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-26 12:30:00NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-21 12:30:00NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-19 12:15:00NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-14 12:15:00NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-12 12:30:00NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-07 12:20:00NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-03-05 12:30:00NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
accesswire.com
2024-02-29 12:20:00NEW YORK, NY / ACCESSWIRE / February 29, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.
Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock
prnewswire.com
2024-01-08 08:00:00SHERMAN, Texas, Jan. 8, 2024 /PRNewswire/ -- TO: All persons and entities who, during the period between November 14, 2016 through December 8, 2021 inclusive, purchased or otherwise acquired the common stock of Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) (the "Settlement Class"), including all persons or entities who purchased or otherwise acquired Reata common stock pursuant and/or traceable to Reata's 2019 Offering and/or 2020 Offering (the "Offerings Subclass"). PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.